BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Terrier B, Pol S, Thibault V, Gottenberg J, Cacoub P. Prise en charge du risque de réactivation du virus de l’hépatite B chez les patients traités par immunosuppresseurs et immunomodulateurs en médecine interne : données de l’enquête REACTI-B et proposition d’un algorithme de prise en charge. La Revue de Médecine Interne 2012;33:4-12. [DOI: 10.1016/j.revmed.2011.07.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Grossi O, Généreau T. Corticoïdes et… infections, dopage, chirurgie et sexualité. La Revue de Médecine Interne 2013;34:269-78. [DOI: 10.1016/j.revmed.2012.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
2 Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine. 2014;81:478-484. [PMID: 24561021 DOI: 10.1016/j.jbspin.2014.01.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
3 Zhou Q, Zhang Q, Wang K, Huang T, Deng S, Wang Y, Cheng C. Anti-rheumatic Drug-induced Hepatitis B Virus Reactivation and Preventive Strategies for Hepatocellular Carcinoma. Pharmacol Res 2022;:106181. [PMID: 35301112 DOI: 10.1016/j.phrs.2022.106181] [Reference Citation Analysis]
4 Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla É, Hamidou M, Harlé JR, Karras A, Lega JC. Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med. 2013;42:1317-1330. [PMID: 24095054 DOI: 10.1016/j.lpm.2013.08.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
5 Costedoat-Chalumeau N, Groh M, Piette JC, Launay O. [How to minimize the risk of infection in systemic lupus erythematosus?]. Rev Med Interne 2019;40:347-50. [PMID: 29937299 DOI: 10.1016/j.revmed.2018.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Droz N, Gilardin L, Cacoub P, Berenbaum F, Wendling D, Godeau B, Piette AM, Dernis E, Ebbo M, Fautrel B. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken). 2013;65:1504-1514. [PMID: 23436730 DOI: 10.1002/acr.21990] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
7 Pol S. Management of HBV in immunocompromised patients. Liver Int. 2013;33 Suppl 1:182-187. [PMID: 23286863 DOI: 10.1111/liv.12055] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
8 Causse X. [How to monitor today HBV immunotolerant patients and inactive chronic HBV carriers?]. Presse Med 2014;43:3-4. [PMID: 24332701 DOI: 10.1016/j.lpm.2013.07.018] [Reference Citation Analysis]